Health

Novo Nordisk's New Weight Loss Drug Outperforms Competitors

Updated 2026-09-28 12:55 UTC 1 source Positive

Novo Nordisk’s new weight loss drug, a potential successor to Wegovy, outperformed Zepbound in clinical trials. The results suggest improved efficacy for patients.

Coverage timeline — 1 article

The Hill

Novo Nordisk's next-gen weight loss drug outperforms Zepbound in new trial

Novo Nordisk says its potential Wegovy successor helped patients lose more weight than Zepbound in a major clinical trial.

2026-09-28 12:23 UTC